“Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients With Moderate-to-Severe Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S1, https://doi.org/10.25251/skin.2.supp.1.